Spanish version of the Mattis Dementia Rating Scale-2 for early detection of Alzheimer's disease and mild cognitive impairment.
We aimed to analyse the clinical utility of the Mattis Dementia Rating Scale (MDRS-2) for early detection of Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) in a sample of Spanish older adults.



A total of 125 participants (age = 75.12 ± 6.83, years of education =7.08 ± 3.57) were classified in three diagnostic groups: 45 patients with mild AD, 37 with amnestic MCI-single and multiple domain and 43 cognitively healthy controls (HCs). Reliability, criterion validity and diagnostic accuracy of the MDRS-2 (total and subscales) were analysed. The MDRS-2 scores, adjusted by socio-demographic characteristics, were calculated through hierarchical multiple regression analysis.



The global scale had adequate reliability (α = 0.736) and good criterion validity (r = 0.760, p < .001) with the Mini-Mental State Examination. The optimal cut-off point between AD patients and HCs was 124 (sensitivity [Se] = 97% and specificity [Sp] = 95%), whereas 131 (Se = 89%, Sp = 81%) was the optimal cut-off point between MCI and HCs. An optimal cut-off point of 123 had good Se (0.97), but poor Sp (0.56) to differentiate AD and MCI groups. The Memory and Initiation/Perseveration subscales had the highest discriminative capacity between the groups.



The MDRS-2 is a reliable and valid instrument for the assessment of cognitive impairment in Spanish older adults. In particular, optimal capacity emerged for the detection of early AD and MCI. Copyright © 2017 John Wiley & Sons, Ltd.
Clinical Research Unit of the University Hospital 12 de Octubre (i+12), Madrid, Spain.
Elina
0000-0002-9506-8491
E
Boycheva
Department of Basic Psychology, Psychobiology and Methodology of Behavioral Science, University of Salamanca, Salamanca, Spain.
Israel
I
Contador
Department of Psychology, Federal University of Paraíba, João Pessoa, Brazil.
Bernardino
0000-0001-8080-5578
B
Fernández-Calvo
Department of Personality, Assessment and Psychological Treatment, University of Salamanca, Salamanca, Spain.
Francisco
F
Ramos-Campos
Department of Neurology, University Hospital 12 de Octubre, Madrid, Spain.
Verónica
V
Puertas-Martín
Department of Neurology, University Hospital 12 de Octubre, Madrid, Spain.
Alberto
A
Villarejo-Galende
Clinical Research Unit of the University Hospital 12 de Octubre (i+12), Madrid, Spain.|Faculty of Medicine, Complutense University, Madrid, Spain.
Félix
F
Bermejo-Pareja
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000523:psychology; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000523:psychology; D042241:Early Diagnosis; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D008297:Male; D008568:Memory; D000073216:Mental Status and Dementia Tests; D008875:Middle Aged; D011594:Psychometrics / Q000592:standards; D012044:Regression Analysis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
Alzheimer's disease; clinical validity; early detection; mild cognitive impairment; neuropsychological assessment; older adults